The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data - PubMed (original) (raw)

doi: 10.1158/2159-8290.CD-12-0095.

Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson, Yevgeniy Antipin, Boris Reva, Arthur P Goldberg, Chris Sander, Nikolaus Schultz

Affiliations

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

Ethan Cerami et al. Cancer Discov. 2012 May.

Erratum in

Abstract

The cBio Cancer Genomics Portal (http://cbioportal.org) is an open-access resource for interactive exploration of multidimensional cancer genomics data sets, currently providing access to data from more than 5,000 tumor samples from 20 cancer studies. The cBio Cancer Genomics Portal significantly lowers the barriers between complex genomic data and cancer researchers who want rapid, intuitive, and high-quality access to molecular profiles and clinical attributes from large-scale cancer genomics projects and empowers researchers to translate these rich data sets into biologic insights and clinical applications.

© 2012 AACR.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Figures

Figure 1

Figure 1

The cBio Cancer Genomics Portal. A, the cBio Cancer Genomics Portal is an open platform for interactively exploring multidimensional cancer genomics data sets in the context of clinical data and biologic pathways. B, OncoPrint of RB pathway alterations in GBM. Genomic alterations of different members in the RB pathway are mutually exclusive. The OncoPrint provides an overview of genomic alterations (legend) in particular genes (rows) affecting particular individual samples (columns). C, mutation details for RB1. The predicted functional impact of the RB1 missense mutations in GBM can be assessed through Mutation Assessor. This includes a predicted functional impact score, a multiple sequence alignment of different family members, and a 3-dimensional structure view, when available. D, correlation plot for CDK4. GBM samples with CDK4 amplification have markedly increased CDK4 mRNA expression. E, survival analysis. GBM cases with an RB pathway alteration have worse overall survival than cases without an RB pathway alteration. F, network view of the BRCA1/BRCA2 neighborhood in serous ovarian cancer. BRCA1 and BRCA2 are seed genes (indicated with thick border), and all other genes are automatically identified as altered in ovarian cancer. Multidimensional genomic details are shown for BRCA2 and C11orf30/EMSY. Darker red indicates increased frequency of alteration (defined by mutation, copy number amplification, or homozygous deletion) in ovarian cancer. G, distribution of BRCA1 mutations in ovarian cancer across protein domains. The 2 hot spots (p.E23fs and p.Q1756fs) represent the common founder mutations 185delAG and 5382insC frequently observed in BRCA1.

Similar articles

Cited by

References

    1. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, et al. International network of cancer genome projects. Nature. 2010;464:993–998. - PMC - PubMed
    1. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–1068. - PMC - PubMed
    1. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615. - PMC - PubMed
    1. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22. - PMC - PubMed
    1. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010;42:715–721. - PMC - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources